ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of va...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Neurol
Päätekijät: Lingor, Paul, Weber, Markus, Camu, William, Friede, Tim, Hilgers, Reinhard, Leha, Andreas, Neuwirth, Christoph, Günther, René, Benatar, Michael, Kuzma-Kozakiewicz, Magdalena, Bidner, Helen, Blankenstein, Christiane, Frontini, Roberto, Ludolph, Albert, Koch, Jan C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2019
Aiheet:
Neurology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6446974/
https://ncbi.nlm.nih.gov/pubmed/30972018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2019.00293
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia